Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics

American Journal of Reproductive Immunology

Volumn 71, Issue 6, 2014, Pages 523-530

  Thurman, Andrea R ^a   Anderson, Sharon ^a   Doncel, Gustavo F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Antiretrovirals; Drug drug interactions; HIV mucosal acquisition; Hormonal contraceptives

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CONTRACEPTIVE AGENT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; MEDROXYPROGESTERONE ACETATE; RITONAVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DEOXYCYTIDINE; EMTRICITABINE; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG MECHANISM; DRUG METABOLISM; FAMILY PLANNING; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; METRORRHAGIA; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNPLANNED PREGNANCY; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; CONTRACEPTION; DRUG EFFECTS; DRUG INTERACTION; FEMALE; HIV INFECTIONS; METABOLISM; PATHOGENICITY; PREGNANCY; PROCEDURES;

ADENINE; ANTI-HIV AGENTS; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DEOXYCYTIDINE; DRUG INTERACTIONS; FAMILY PLANNING SERVICES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHONATES; PREGNANCY; PROGESTINS; TREATMENT OUTCOME;

EID: 84900836244     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12210     Document Type: Article

References (64)

1. UNAIDS: Report on the Global AIDS Epidemic, 2012.
2. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Talijaard M, Piper J, Gomez Feliciano K: Pre-Exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Atlanta, GA, CROI 2013, 2013.
3. van der Linde I: HIV/AIDS in South Africa: At last the glass if half full. 6th SA AIDS Conference. Durban, South Africa, 2013.
4. Maternal Mortality in 2005, 2005. (Accessed 07/15/2010, at http://whqlibdoc.who.int/publications/2007/9789241596213_eng.pdf).
5. Singh S, Wulf D, Hussain R, Bankole A, Sedgh G: Abortion Worldwide: A Decade of Uneven Progress. New York, Guttmacher Institute, 2009.
6. Singh S, Sedgh G, Hussain R: Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann 2010; 41:241-250.
7. World Contraceptive Use 2011, 2011. (Accessed 7/15/2011, at http://www.un.org/esa/population/publications/wcu2010/Data/UNPD_WCU_2010_Contraceptive_prevalence_method.xls).
8. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 10.1126(1193748):1.
9. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, Gabillard D, Sorho S, Rouet F, Eholie S, Anglaret X: Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35.
10. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, Chiba K: Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 2000; 6:3297-3303.
11. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78:260-277.
12. Guengerich FP: Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990; 47:1981-1988.
13. Sevinsky H, Eley T, Persson A, Garner D, Yones C, Nettles R, Krantz K, Bertz R, Zhang J: The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther 2011; 16:149-156.
14. Robinson JA, Jamshidi R, Burke AE: Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol 2012; 2012:890160.
15. Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R: The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011; 16:157-164.
16. American College of Obstetricians and Gynecologists. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions, reaffirmed 2011. Obstet Gynecol 2006; 107:1453-1472.
17. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W: Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91:852-858.
18. Zhou T, Hu M, Cost M, Poloyac S, Rohan L: Expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. AIDS Res Hum Retroviruses 2013; 29:1496-1503.
19. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42:612-617.
20. Hunsucker SA, Mitchell BS, Spychala J: The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005; 107:1-30.
21. Biswas N, Rodriguez-Garcia M, Crist SG, Shen Z, Bodwell JE, Fahey JV, Wira CR: Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells. PLoS ONE 2013; 8:e78814.
22. Shen Z, Fahey JV, Bodwell JE, Rodriguez-Garcia M, Rossoll RM, Crist SG, Patel MV, Wira CR: Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts. PLoS ONE 2013; 8:e69854.
23. AIDS Info: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient, 2013. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start.
24. Kearney BP, Mathias A: Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy 2009; 29:924-929.
25. WHO: World Health Organization List of Essential Medicines 18th List April 2013, 2013. http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf.
26. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH: The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 2006; 20:1833-1841.
27. Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, Hoetelmans RM: Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther 2008; 13:563-569.
28. Frohlich M, Burhenne J, Martin-Facklam M, Weiss J, von Wolff M, Strowitzki T, Walter-Sack I, Haefeli WE: Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004; 57:244-252.
29. Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ: Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81:222-227.
30. World Health Organization: Medical Eligibility Criteria for Contraceptive Use 2010, 2010.
31. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, Robinson P: Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002; 29:471-477.
32. Scholler-Gyure M, Kakuda TN, Woodfall B, Aharchi F, Peeters M, Vandermeulen K, Hoetelmans RM: Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009; 80:44-52.
33. Chu JH, Gange SJ, Anastos K, Minkoff H, Cejtin H, Bacon M, Levine A, Greenblatt RM: Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005; 161:881-890.
34. Hubacher D, Liku J, Kiarie J, Rakwar J, Muiruri P, Omwenga J, Chen PL: Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya. J Int AIDS Soc 2013; 16:18448.
35. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J: The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011; 204:e1-e4.
36. Food and Drug Administration: FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection, 2012.
37. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montova-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
38. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Rendkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
39. Radzio J, Hanley K, Mitchell J, Bachman S, Deyounks F, Heneine W, Garcia Lerma G: The Injectable Contraceptive Depo-Provera Does Not Reduce the Prophylactic Efficacy of Truvada in Pigtail Macaques. Atlanta, GA, CROI 2013, 2013.
40. Polis CB, Phillips SJ, Curtis KM: Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS 2013; 27:493-505.
41. Reynolds HW, Janowitz B, Homan R, Johnson L: The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis 2006; 33:350-356.
42. Centers for Disease Control and Prevention: U.S. medical eligibility criteria for contraceptive use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. MMWR 2010; 59:1-86.
43. Rivera R, Yacobson I, Grimes D: The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999; 181:1263-1269.
44. Sondheimer SJ: Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis 2008; 81:19-22.
45. Moreau C, Trussell J, Gilbert F, Bajos N, Bouyer J: Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol 2007; 109:1277-1285.
46. Piegsa K, Guillebaud J: Oral contraceptives and the risk of DVT. Practitioner 1996; 240:544-551.
47. World Health Organization: Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346:1575-1582.
48. GlaxoSmithKline: Study APV10020. A Phase I, open-label, two period, single-sequence, drug-drug interaction study comparing steady-state plasma ethinyl estradiol and norethisterone pharmacokinetics following administration of brevinor for 21 days with and without fosamprenavir 700 mg twice daily (BID) and ritonavir 100 mg BID for 21 days in healthy adult female subjects, 2009.
49. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E: Why consider vaginal drug administration? Fertil Steril 2004; 82:1-12.
50. Henzl MR, Loomba PK: Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 2003; 48:525-540.
51. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE: Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr 2010; 55:473-482.
52. Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, Clax PA, Muderspach L, Lertora JJ: Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008; 77:84-90.
53. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S: Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz. Infect Dis Obstet Gynecol 2012; 2012:137192.
54. Bristol Meyers Squibb: Sustiva Prescribing Information, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020972s033, 021360s021lbl.pdf.
55. The Antiviral Pregnancy Registry: The Antiretroviral Pregnancy Registry, 2012. apregistry.com.
56. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A: Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012; 85:425-427.
57. Matiluko AA, Soundararjan L, Hogston P: Early contraceptive failure of implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007; 33:277-278.
58. Lakhi N, Govind A: Implanon failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Health Care 2010; 36:181-182.
59. McCarty EJ, Keane H, Quinn K, Quah S: Implanon(R) failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS 2011; 22:413-414.
60. Davis KR, Weller SC: The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272-279.
61. Gallo MF, Grimes DA, Lopez LM, Schulz KF: Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2006:CD003550.
62. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS: Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:327-331.
63. Niruthisard S, Roddy RE, Chutivongse S: The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991; 18:176-179.
64. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39:1-8.